Find Your Next Life Science Partner

Reduce partnership selection timeline | Send RFP Requests | Showcase thought leadership | Communicate directly through the platform

821

Listings

Featured

Recommended

101

Liked

FEATURED LISTINGS

Numerof & Associates

Numerof provides customized strategy and implementation solutions for market access, medical affairs, and commercialization challenges across the healthcare industry. With over 30 years’ experience working globally across pharma, device, diagnosti... View More

Drug Information Associ...

Accelerating Innovation and Collaboration in Drug Information: Empowering Professionals in the Global Healthcare Product Development Landscape In today's rapidly evolving healthcare landscape, drug information professionals play a critical role in... View More

FDA CDER Small Business...

CDER SBIA is often the first stop for a small pharmaceutical business trying to contact the Agency. Our goal is to help small pharmaceutical business and industry navigate the wealth of information that FDA offers, and to assist in understanding hu... View More

FEATURED CONTENT

View All

AI & Automation Webinar with Synterex an...

In Part 2 of this webinar, our panel continues to look at implications of AI and automation for businesses with final key messages.

Posted by : Elizabeth P. from Synterex, Inc.

5 hours ago

AI & Automation Webinar with Synterex an...

In Part 1 of this webinar, our panel delves into AI and automation in the business context and weighs the risks and benefits of these technologies in the increasingly digital business landscape.

Posted by : Elizabeth P. from Synterex, Inc.

5 hours ago

This One’s for the Children: Progress in...

Prior to the FD&C Act, pharmaceutical companies were not required to provide proof of drug safety or a disclosure of all active ingredients. Since then, all new drugs undergo an intensive review process by the Food and Drug Administration (FDA), and ever-evolving guidance and regulations ensure that both new drugs and those with updated characteristics, such as dosing, delivery, and expanded indications, are safe and effective for the intended populations. A gap remains, however, for drug investigations including and targeted for children of varying ages.

Posted by : Elizabeth P. from Synterex, Inc.

6 hours ago

The Road to Representation in Clinical R...

Innovative development of human drugs, biologics, and medical devices (medical products) and their quick advancement through the United States Food and Drug Administration (FDA) approval pipeline is necessary to improve the lives of patients. It is also imperative for sponsors to consider diversity when enrolling study participants throughout the clinical development pipeline to adequately represent the population of patients who have a disease or condition.

Posted by : Elizabeth P. from Synterex, Inc.

6 hours ago